AU2004268145B2 - Poly-PEGylated protease inhibitors - Google Patents

Poly-PEGylated protease inhibitors Download PDF

Info

Publication number
AU2004268145B2
AU2004268145B2 AU2004268145A AU2004268145A AU2004268145B2 AU 2004268145 B2 AU2004268145 B2 AU 2004268145B2 AU 2004268145 A AU2004268145 A AU 2004268145A AU 2004268145 A AU2004268145 A AU 2004268145A AU 2004268145 B2 AU2004268145 B2 AU 2004268145B2
Authority
AU
Australia
Prior art keywords
kunitz domain
preparation
compound
protease
kda
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2004268145A
Other languages
English (en)
Other versions
AU2004268145A1 (en
Inventor
Robert Charles Ladner
Arthur C. Ley
Aaron K. Sato
Mark Stochl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of AU2004268145A1 publication Critical patent/AU2004268145A1/en
Application granted granted Critical
Publication of AU2004268145B2 publication Critical patent/AU2004268145B2/en
Priority to AU2010257259A priority Critical patent/AU2010257259B2/en
Assigned to TAKEDA PHARMACEUTICAL COMPANY LIMITED reassignment TAKEDA PHARMACEUTICAL COMPANY LIMITED Request for Assignment Assignors: DYAX CORP.
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2004268145A 2003-08-29 2004-08-30 Poly-PEGylated protease inhibitors Expired AU2004268145B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2010257259A AU2010257259B2 (en) 2003-08-29 2010-12-16 Poly-PEGylated protease inhibitors

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US49884503P 2003-08-29 2003-08-29
US60/498,845 2003-08-29
US59896704P 2004-08-04 2004-08-04
US60/598,967 2004-08-04
PCT/US2004/028257 WO2005021557A2 (en) 2003-08-29 2004-08-30 Poly-pegylated protease inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2010257259A Division AU2010257259B2 (en) 2003-08-29 2010-12-16 Poly-PEGylated protease inhibitors

Publications (2)

Publication Number Publication Date
AU2004268145A1 AU2004268145A1 (en) 2005-03-10
AU2004268145B2 true AU2004268145B2 (en) 2010-09-16

Family

ID=34278618

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2004268145A Expired AU2004268145B2 (en) 2003-08-29 2004-08-30 Poly-PEGylated protease inhibitors
AU2010257259A Expired AU2010257259B2 (en) 2003-08-29 2010-12-16 Poly-PEGylated protease inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2010257259A Expired AU2010257259B2 (en) 2003-08-29 2010-12-16 Poly-PEGylated protease inhibitors

Country Status (9)

Country Link
US (4) US20050089515A1 (enExample)
EP (1) EP1663281B1 (enExample)
JP (4) JP4739207B2 (enExample)
AU (2) AU2004268145B2 (enExample)
CA (2) CA2536873C (enExample)
DK (1) DK1663281T3 (enExample)
ES (1) ES2447423T3 (enExample)
PT (1) PT1663281E (enExample)
WO (1) WO2005021557A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT737207E (pt) * 1994-01-11 2005-02-28 Dyax Corp Inibidores de plasmina humana derivados de dominios kunitz
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US20020065397A1 (en) * 2000-10-12 2002-05-30 Joseph Roberts Protecting therapeutic compositions from host-mediated inactivation
US20050222023A1 (en) * 2002-02-07 2005-10-06 Hans-Peter Hauser Albumin-fused kunitz domain peptides
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
US7064107B2 (en) 2002-06-07 2006-06-20 Dyax Corp. Prevention and reduction of blood loss
ES2395014T3 (es) 2002-08-28 2013-02-07 Dyax Corp. Métodos para conservar órganos y tejidos
US20070020252A1 (en) * 2003-08-29 2007-01-25 Ladner Robert C Modified protease inhibitors
CA2536873C (en) * 2003-08-29 2019-09-10 Dyax Corp. Poly-pegylated protease inhibitors
CA2559285A1 (en) * 2004-03-18 2005-09-29 Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
US20070293539A1 (en) * 2004-03-18 2007-12-20 Lansbury Peter T Methods for the treatment of synucleinopathies
CA2559221A1 (en) * 2004-03-18 2005-09-29 Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
US20050288298A1 (en) * 2004-03-18 2005-12-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
JP2008520729A (ja) * 2004-11-22 2008-06-19 ダイアックス コーポレーション プラスミン阻害療法
AU2006332774A1 (en) * 2005-12-29 2007-07-12 Dyax Corp. Protease inhibition
EP2001500A4 (en) * 2006-03-10 2010-07-28 Dyax Corp FORMULATIONS FOR ECALLANTIDE
SI1854477T1 (sl) 2006-03-16 2017-01-31 Dyax Corp. Peptidi, ki inhibirajo plazma kalikrein za uporabo pri zdravljenju očesnih motenj
ES2682646T3 (es) * 2006-03-16 2018-09-21 Dyax Corp. Composiciones y métodos para el tratamiento de trastornos oftálmicos
US20090075887A1 (en) * 2007-08-21 2009-03-19 Genzyme Corporation Treatment with Kallikrein Inhibitors
US20090105142A1 (en) * 2007-08-23 2009-04-23 Genzyme Corporation Treatment with kallikrein inhibitors
US8637454B2 (en) 2009-01-06 2014-01-28 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
AU2011204349C1 (en) 2010-01-06 2017-02-16 Takeda Pharmaceutical Company Limited Plasma kallikrein binding proteins
WO2012094587A1 (en) 2011-01-06 2012-07-12 Dyax Corp. Plasma kallikrein binding proteins
US9402919B2 (en) 2011-03-04 2016-08-02 Intrexon Corporation Vectors conditionally expressing protein
KR102256613B1 (ko) 2011-09-08 2021-05-27 프레시전 인코포레이티드 결정성 디아실하이드라진 및 이의 용도
CN103230216B (zh) 2013-05-03 2016-01-20 武汉苏泊尔炊具有限公司 不粘锅
US10428158B2 (en) 2014-03-27 2019-10-01 Dyax Corp. Compositions and methods for treatment of diabetic macular edema
IL311156A (en) 2015-12-11 2024-04-01 Takeda Pharmaceuticals Co Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
WO2019032472A1 (en) * 2017-08-08 2019-02-14 The Board Of Trustees Of The Leland Stanford Junior University HIGH AFFINITY MODIFIED MATRIX INHIBITOR
CN108676068B (zh) * 2018-04-24 2022-09-23 厦门东风精准医药科技有限公司 一种抗炎灵类化合物及其制备方法
WO2020023387A1 (en) * 2018-07-23 2020-01-30 Sienna Biopharmaceuticals, Inc. Uses of polymer conjugates of indolocarbazole compounds with reduced exposure

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990237A (en) * 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
US6423498B1 (en) * 1994-01-11 2002-07-23 Dyax Corp. Variegated Kunitz domain peptide library and uses thereof
US20030100070A1 (en) * 1999-12-22 2003-05-29 Holloway James L. Kunitz domain polypeptide Zkun11

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
US4289747A (en) 1978-12-26 1981-09-15 E-Y Laboratories, Inc. Immunological determination using lectin
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
JPH0623113B2 (ja) 1986-01-31 1994-03-30 浩 前田 癌性胸・腹水貯留抑制剤
DK225488D0 (da) * 1988-04-26 1988-04-26 Novo Industri As Polypeptid
US7078383B2 (en) 1988-09-02 2006-07-18 Dyax Corp. ITI-D1 Kunitz domain mutants as HNE inhibitors
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5663143A (en) * 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
DE69034007T2 (de) 1989-04-28 2003-05-08 Riker Laboratories Inc., Northridge Inhalationsvorrichtung für Trockenpulver
US5278285A (en) * 1990-02-01 1994-01-11 Bayer Aktiengesellschaft Variant of Kunitz-type inhibitor derived from the α3-chain of human type VI collagen produced by recombinant DNA technology
US5278144A (en) * 1990-09-04 1994-01-11 Cor Therapeutics, Inc. Antithrombosis agents
US5583107A (en) * 1990-09-04 1996-12-10 Cor Therapeutics, Inc. Agents affecting thrombosis and hemostasis
US5370901A (en) 1991-02-15 1994-12-06 Bracco International B.V. Compositions for increasing the image contrast in diagnostic investigations of the digestive tract of patients
US20030223977A1 (en) 1991-03-01 2003-12-04 Ley Arthur Charles Kunitz domain mutants as cathepsin G inhibitors
US5166133A (en) * 1991-04-17 1992-11-24 Cetus Corporation Method for inhibing adhesion of white blood cells to endothelial cells
IL104324A0 (en) 1992-01-07 1993-05-13 Novo Nordisk As Variant of human kunitz-type protease inhibitor
IL104325A (en) 1992-01-07 2000-10-31 Novo Nordisk As Variants of human kunitz-type protease inhibitor domain II of tissue factor pathway inhibitor (TFPI) pharmaceutical compositions containing them a DNA construct encoding them their expression vectors a cell containing said DNA constructs and methods for the production of all the above
IL104326A0 (en) 1992-01-07 1993-05-13 Novo Nordisk As Variant of human kunitz-type protease inhibitor
JP3929484B2 (ja) * 1993-09-14 2007-06-13 ジェネンテック・インコーポレーテッド エコチンおよびその同族体を含む医薬的組成物
US5446090A (en) * 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US6057287A (en) * 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
EP0739355B1 (en) * 1994-01-11 2004-09-08 Dyax Corporation Kallikrein-inhibiting "kunitz domain" proteins and analogues thereof
US5795954A (en) * 1994-03-04 1998-08-18 Genentech, Inc. Factor VIIa inhibitors from Kunitz domain proteins
US5589359A (en) * 1994-08-05 1996-12-31 Chiron Corporation Chimeric proteins
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5695760A (en) * 1995-04-24 1997-12-09 Boehringer Inglehiem Pharmaceuticals, Inc. Modified anti-ICAM-1 antibodies and their use in the treatment of inflammation
US5804376A (en) * 1995-05-02 1998-09-08 Incyte Pharmaceuticals, Inc. Pancreas-derived serpin
US5780265A (en) * 1995-06-05 1998-07-14 Genentech, Inc. Kunitz type plasma kallikrein inhibitors
US5786328A (en) * 1995-06-05 1998-07-28 Genentech, Inc. Use of kunitz type plasma kallikrein inhibitors
US5672662A (en) * 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
SE9502800D0 (sv) 1995-08-10 1995-08-10 Astra Ab Disposable inhaler
JPH11512439A (ja) * 1995-09-14 1999-10-26 エルエックスアール バイオテクノロジー インコーポレイテッド リン脂質の混合物を含む抗アポトーシス活性を有する組成物
KR19990063648A (ko) * 1995-09-21 1999-07-26 프레드한 아룬디프 에스 글루타민산 데카복실라제에 대한 항체와 폴리(에틸렌 글리콜)공액물을 섬세포에 제공하는 방법
US5736364A (en) * 1995-12-04 1998-04-07 Genentech, Inc. Factor viia inhibitors
US6214966B1 (en) * 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
US6258351B1 (en) * 1996-11-06 2001-07-10 Shearwater Corporation Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels
JP2003525845A (ja) * 1997-10-28 2003-09-02 ヴィヴァス・インコーポレイテッド 勃起機能不全の処置のためのホスホジエステラーゼインヒビターの局所投与
PT1053019E (pt) * 1998-01-07 2004-04-30 Debio Rech Pharma Sa Acrilatos de poli(etileno-glicol) heterobifuncional degradaveis e geles e conjugados derivados dos mesmos
EP1411075B1 (en) * 1998-03-12 2008-07-02 Nektar Therapeutics Al, Corporation Method for preparing polymer conjugates
EP0985697B1 (en) * 1998-03-24 2006-01-04 Nof Corporation Oxirane derivatives and process for producing the same
US6017723A (en) * 1998-03-27 2000-01-25 Long Island Jewish Medical Center Method for isolating inhibitors of protease activity
US6001596A (en) * 1998-05-07 1999-12-14 Incyte Pharmaceuticals, Inc. Growth-associated protease inhibitor heavy chain precursor
US6087473A (en) * 1999-05-26 2000-07-11 Zymogenetics, Inc. Kunitz domain polypeptide and materials and methods for making it
DE69943205D1 (de) * 1998-08-06 2011-03-31 Mountain View Pharmaceuticals Peg-uricase Konjugate und Verwendung davon
US6783965B1 (en) * 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
US6565874B1 (en) * 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
JP2002531089A (ja) * 1998-11-30 2002-09-24 イーライ・リリー・アンド・カンパニー 赤血球産生性化合物
US6180607B1 (en) * 1999-08-05 2001-01-30 Christopher Davies Protein having proteinase inhibitor activity
KR20020065517A (ko) * 1999-11-12 2002-08-13 맥시겐 홀딩스 리미티드 인터페론 감마 접합체
US6348558B1 (en) * 1999-12-10 2002-02-19 Shearwater Corporation Hydrolytically degradable polymers and hydrogels made therefrom
AU781729B2 (en) * 1999-12-22 2005-06-09 Nektar Therapeutics Method for the preparation of 1-benzotriazolyl carbonate esters of poly(ethylene glycol)
US6413507B1 (en) * 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
US20020102703A1 (en) * 1999-12-29 2002-08-01 Sheppard Paul O. Kunitz domain polypeptide zkun10
AU2001294541A1 (en) * 2000-09-08 2002-03-22 Schering Corporation Mammalian genes; related reagents and methods
ES2203601T3 (es) * 2000-10-31 2004-04-16 Debiopharm S.A. Suspension de una proteina de epi-hne, metodo para su preparacion, un aerosol en forma de polvo seco derivado de la misma, compuestos farmaceuticos que comprenden dicha suspension o dicho aerosol y sus utilizaciones.
TW593427B (en) * 2000-12-18 2004-06-21 Nektar Therapeutics Al Corp Synthesis of high molecular weight non-peptidic polymer derivatives
JP2004531550A (ja) * 2001-05-11 2004-10-14 アラダイム コーポレーション 吸入によって送達されるタンパク質の、分子性状の最適化方法および製剤
OA13136A (en) * 2001-05-21 2006-12-13 Nektar Therapeutics Pulmonary administration of chemically modified insulin.
US7153829B2 (en) * 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
US7064107B2 (en) * 2002-06-07 2006-06-20 Dyax Corp. Prevention and reduction of blood loss
DE60335111D1 (de) * 2002-07-24 2011-01-05 Hoffmann La Roche Pegyliertes t20-polypeptid
AU2003258518B2 (en) * 2002-07-24 2007-01-18 F. Hoffmann-La Roche Ag Polyalkylene glycol acid additives
ES2395014T3 (es) 2002-08-28 2013-02-07 Dyax Corp. Métodos para conservar órganos y tejidos
US8129330B2 (en) 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US20040062748A1 (en) * 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US7314613B2 (en) * 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
DK1667708T5 (da) 2002-12-26 2012-11-12 Mountain View Pharmaceuticals Polyethylenglycolkonjugater af interferon-beta-1b med forøget biologisk styrke in vitro
US6989369B2 (en) * 2003-02-07 2006-01-24 Dyax Corp. Kunitz domain peptides
US20070020252A1 (en) 2003-08-29 2007-01-25 Ladner Robert C Modified protease inhibitors
CA2536873C (en) 2003-08-29 2019-09-10 Dyax Corp. Poly-pegylated protease inhibitors
US20060228331A1 (en) * 2003-10-10 2006-10-12 Novo Nordisk A/S IL-21 Derivatives and variants
US7235530B2 (en) * 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
JP2008520729A (ja) * 2004-11-22 2008-06-19 ダイアックス コーポレーション プラスミン阻害療法
AU2006332774A1 (en) * 2005-12-29 2007-07-12 Dyax Corp. Protease inhibition
US7276480B1 (en) * 2005-12-30 2007-10-02 Dyax Corp. Prevention and reduction of blood loss
EP2001500A4 (en) * 2006-03-10 2010-07-28 Dyax Corp FORMULATIONS FOR ECALLANTIDE
ES2682646T3 (es) * 2006-03-16 2018-09-21 Dyax Corp. Composiciones y métodos para el tratamiento de trastornos oftálmicos
US8637454B2 (en) * 2009-01-06 2014-01-28 Dyax Corp. Treatment of mucositis with kallikrein inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6423498B1 (en) * 1994-01-11 2002-07-23 Dyax Corp. Variegated Kunitz domain peptide library and uses thereof
US5990237A (en) * 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
US20030100070A1 (en) * 1999-12-22 2003-05-29 Holloway James L. Kunitz domain polypeptide Zkun11

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MOLINEUX, G., Cancer Treatment Reviews, 2002, Vol. 28, Suppl. A, pages 13-16 (Y) *
ROBERTS, M.J. et al., Advanced Drug Delivery Rev., 2002, Vol. 54, pages 459-76 (Y) *
WARK, P.A.B., iDrugs, 2002, Vol. 5, pages 586-89 (Y) *

Also Published As

Publication number Publication date
EP1663281B1 (en) 2013-12-25
JP5396346B2 (ja) 2014-01-22
WO2005021557A3 (en) 2006-02-16
JP4739207B2 (ja) 2011-08-03
US20110172140A1 (en) 2011-07-14
CA2536873C (en) 2019-09-10
DK1663281T3 (en) 2014-03-17
US20050089515A1 (en) 2005-04-28
CA3050564A1 (en) 2005-03-10
US20070041959A1 (en) 2007-02-22
ES2447423T3 (es) 2014-03-12
JP2011231115A (ja) 2011-11-17
US7550427B2 (en) 2009-06-23
EP1663281A2 (en) 2006-06-07
AU2010257259A1 (en) 2011-01-13
PT1663281E (pt) 2014-03-17
WO2005021557A2 (en) 2005-03-10
AU2004268145A1 (en) 2005-03-10
CA2536873A1 (en) 2005-03-10
EP1663281A4 (en) 2009-02-18
JP2010254708A (ja) 2010-11-11
JP2007504170A (ja) 2007-03-01
JP2014129391A (ja) 2014-07-10
AU2010257259B2 (en) 2014-06-19
US20120322744A1 (en) 2012-12-20

Similar Documents

Publication Publication Date Title
AU2010257259B2 (en) Poly-PEGylated protease inhibitors
JP2007504170A5 (enExample)
JP5632126B2 (ja) プロテアーゼ阻害
US20070020252A1 (en) Modified protease inhibitors
JP4137997B2 (ja) クニッツドメインから誘導されたヒトプラスミンの阻害剤
JP2006512050A (ja) 血清タンパク質結合標的特異的リガンドとその同定方法
JP2018093882A (ja) Ｔｆｐｉ−２の変異体クニッツドメインｉに関連した方法および組成物
EP1835926A2 (en) Plasmin-inhibitory therapies
WO2005041631A2 (en) Endotheliase-1 ligands
HK1092710A (en) Poly-pegylated protease inhibitors
HK1092710B (en) Poly-pegylated protease inhibitors
AU2013202021B2 (en) Methods and compositions related to mutant Kunitz domain of TFPI-2

Legal Events

Date Code Title Description
MK24 Application lapsed reg. 22.2e(2) - failure to pay response fee
NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO PAY THE EXAMINATION RESPONSE FEE HAS BEEN EXTENDED TO 23 DEC 2010.

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Free format text: FORMER OWNER(S): DYAX CORP.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired